Cargando…

P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation

The global SARS-CoV-2 pandemic starting in 2019 has already reached more than 2.3 million deaths. Despite the scientific community’s efforts to investigate the COVID-19 disease, a drug for effectively treating or curing patients yet needs to be discovered. Hematopoietic stem cells (HSC) differentiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lintzmaier Petiz, Lyvia, Glaser, Talita, Scharfstein, Julio, Ratajczak, Mariusz Z., Ulrich, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877512/
https://www.ncbi.nlm.nih.gov/pubmed/33575962
http://dx.doi.org/10.1007/s12015-021-10129-7
_version_ 1783650183025786880
author Lintzmaier Petiz, Lyvia
Glaser, Talita
Scharfstein, Julio
Ratajczak, Mariusz Z.
Ulrich, Henning
author_facet Lintzmaier Petiz, Lyvia
Glaser, Talita
Scharfstein, Julio
Ratajczak, Mariusz Z.
Ulrich, Henning
author_sort Lintzmaier Petiz, Lyvia
collection PubMed
description The global SARS-CoV-2 pandemic starting in 2019 has already reached more than 2.3 million deaths. Despite the scientific community’s efforts to investigate the COVID-19 disease, a drug for effectively treating or curing patients yet needs to be discovered. Hematopoietic stem cells (HSC) differentiating into immune cells for defense express COVID-19 entry receptors, and COVID-19 infection hinders their differentiation. The importance of purinergic signaling in HSC differentiation and innate immunity has been recognized. The metabotropic P2Y14 receptor subtype, activated by UDP-glucose, controls HSC differentiation and mobilization. Thereon, the exacerbated activation of blood immune cells amplifies the inflammatory state observed in COVID-19 patients, specially through the continuous release of reactive oxygen species and extracellular neutrophil traps (NETs). Further, the P2Y14 subtype, robustly inhibits the infiltration of neutrophils into various epithelial tissues, including lungs and kidneys. Here we discuss findings suggesting that antagonism of the P2Y14 receptor could prevent the progression of COVID-19-induced systemic inflammation, which often leads to severe illness and death cases. Considering the modulation of neutrophil recruitment of extreme relevance for respiratory distress and lung failure prevention, we propose that P2Y14 receptor inhibition by its selective antagonist PPTN could limit neutrophil recruitment and NETosis, hence limiting excessive formation of oxygen reactive species and proteolytic activation of the kallikrein-kinin system and subsequent bradykinin storm in the alveolar septa of COVID-19 patients. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7877512
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-78775122021-02-16 P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation Lintzmaier Petiz, Lyvia Glaser, Talita Scharfstein, Julio Ratajczak, Mariusz Z. Ulrich, Henning Stem Cell Rev Rep Article The global SARS-CoV-2 pandemic starting in 2019 has already reached more than 2.3 million deaths. Despite the scientific community’s efforts to investigate the COVID-19 disease, a drug for effectively treating or curing patients yet needs to be discovered. Hematopoietic stem cells (HSC) differentiating into immune cells for defense express COVID-19 entry receptors, and COVID-19 infection hinders their differentiation. The importance of purinergic signaling in HSC differentiation and innate immunity has been recognized. The metabotropic P2Y14 receptor subtype, activated by UDP-glucose, controls HSC differentiation and mobilization. Thereon, the exacerbated activation of blood immune cells amplifies the inflammatory state observed in COVID-19 patients, specially through the continuous release of reactive oxygen species and extracellular neutrophil traps (NETs). Further, the P2Y14 subtype, robustly inhibits the infiltration of neutrophils into various epithelial tissues, including lungs and kidneys. Here we discuss findings suggesting that antagonism of the P2Y14 receptor could prevent the progression of COVID-19-induced systemic inflammation, which often leads to severe illness and death cases. Considering the modulation of neutrophil recruitment of extreme relevance for respiratory distress and lung failure prevention, we propose that P2Y14 receptor inhibition by its selective antagonist PPTN could limit neutrophil recruitment and NETosis, hence limiting excessive formation of oxygen reactive species and proteolytic activation of the kallikrein-kinin system and subsequent bradykinin storm in the alveolar septa of COVID-19 patients. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-02-11 2021 /pmc/articles/PMC7877512/ /pubmed/33575962 http://dx.doi.org/10.1007/s12015-021-10129-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Lintzmaier Petiz, Lyvia
Glaser, Talita
Scharfstein, Julio
Ratajczak, Mariusz Z.
Ulrich, Henning
P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title_full P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title_fullStr P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title_full_unstemmed P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title_short P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo‐inflammation
title_sort p2y14 receptor as a target for neutrophilia attenuation in severe covid-19 cases: from hematopoietic stem cell recruitment and chemotaxis to thrombo‐inflammation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877512/
https://www.ncbi.nlm.nih.gov/pubmed/33575962
http://dx.doi.org/10.1007/s12015-021-10129-7
work_keys_str_mv AT lintzmaierpetizlyvia p2y14receptorasatargetforneutrophiliaattenuationinseverecovid19casesfromhematopoieticstemcellrecruitmentandchemotaxistothromboinflammation
AT glasertalita p2y14receptorasatargetforneutrophiliaattenuationinseverecovid19casesfromhematopoieticstemcellrecruitmentandchemotaxistothromboinflammation
AT scharfsteinjulio p2y14receptorasatargetforneutrophiliaattenuationinseverecovid19casesfromhematopoieticstemcellrecruitmentandchemotaxistothromboinflammation
AT ratajczakmariuszz p2y14receptorasatargetforneutrophiliaattenuationinseverecovid19casesfromhematopoieticstemcellrecruitmentandchemotaxistothromboinflammation
AT ulrichhenning p2y14receptorasatargetforneutrophiliaattenuationinseverecovid19casesfromhematopoieticstemcellrecruitmentandchemotaxistothromboinflammation